A total of 43 T2DM-related targets were obtained via network pharmacological prediction, mainly focusing on EGFR tyrosine kinase inhibitor resistance, endocrine resistance, the PI3K-Akt signaling pathway, and the Rap1 signaling pathway. This evidence concerns the gene EGFR and type 2 diabetes mellitus.